Day: August 14, 2024

Agrify Corporation Announces Results for Second Quarter 2024 and Amended Results for First Quarter 2024

TROY, Mich., Aug. 14, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Summary Revenue was $3.0 million for the second quarter of 2024, compared to $2.6 million for the first quarter of 2024 and $5.1 million for the second quarter of 2023. Gross profit was $1.7 million for the second quarter of 2024, compared to $0.7 million for the first quarter of 2024 and $0.6 million for the second quarter of 2023.  Operating loss was $1.5 million for the second quarter of 2024, compared to $5.3 million in the second quarter of 2023. Net loss for the second quarter of 2024 was $2.8 million, compared...

Continue reading

Enservco Corporation Reports Results for Second Quarter 2024

Recently Announced Transactions Expected to Benefit Operating and Financial Performance in Second Half 2024 and Beyond LONGMONT, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) — Enservco Corporation (NYSE American: ENSV) (“Enservco”, or the “Company”), a diversified provider of energy logistics solutions and specialized well-site services to the domestic energy industry, today announced operational and financial results for the second quarter of 2024. The Company announced on August 9, 2024 the sale of certain Colorado based frac water heating assets of Heat Waves Hot Oil Service, LLC, a wholly owned subsidiary of Enservco, and its exit from the frac water heating business in Colorado. The financial results for Colorado frac water heating services are reported in the Company’s “Completion and Other Services” segment in Enservco’s financial...

Continue reading

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS) Marker Therapeutics to receive $2 million funding from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma HOUSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the second quarter ended June 30, 2024. “The second...

Continue reading

Safe & Green Holdings Reports Second Quarter 2024 Results and Provides a Business Update

Gross profit increases over four-fold; operating expenses reduced 48% Reports record sales pipeline in excess of $25 million On track to achieve positive cash flow before year-end MIAMI, Aug. 14, 2024 (GLOBE NEWSWIRE) — Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures, reported results for the three months ended June 30, 2024. Key Highlights: Record sales pipeline in excess of $25 million and positive outlook for H2 2024 Gross profit margin in Q2 2024 increased to 12.7% compared to 0.7% for Q2 2023 Operating expenses declined by $2.7 million in Q2 2024 versus the same period last year Company reaffirms guidance it is on track to achieve positive cash flow before year-end Received a term sheet from a premier lender...

Continue reading

XWELL, Inc. Reports Second Quarter 2024 Results

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today reported results for the second quarter ended June 30, 2024. Recent Highlights: XWELL delivered 2024 second quarter revenue growth of approximately 14% from the comparable quarter in 2023 driven by stronger demand for services and retail products. In June, XpresSpa opened a new spa in Philadelphia International Airport — its first in a U.S. airport in more than 5 years and the first to leverage the Company’s “labor-lite, tech-forward” offering. In June, the CDC issued a new three-year biosurveillance program RFP which XpresTest is answering and, if awarded, will commence during the third quarter of 2024. It is anticipated that the value of...

Continue reading

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three and six months ended June 30, 2024 and provided a business update. Highlights from the second quarter of 2024 and subsequent weeks included the following: Total revenues for the second quarter of 2024 were $7.8 million, a 34% increase from the same period of the prior year Cash and cash equivalents were $4.4 million as of June 30, 2024, compared with $1.3 million on December 31, 2023 Biofrontera announced the launch of a new, FDA-approved red-light source, the RhodoLED® XL lamp in June and installed several lamps by June 30th, 2024 Took control of all clinical trials relating to Ameluz®...

Continue reading

BIO-key Reports Reduced Net Loss and Cash Used in Operations on Lower Q2’24 Revenues; Hosts Investor Call Thu. Aug. 15th at 10am ET

HOLMDEL, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its second quarter ended June 30, 2024 (Q2’24). Note, BIO-key’s results for 2023 were restated at year-end and filed with the Company’s 2023 Form 10-K, and as a result Q2’23 and six months ended June 30, 2023 comparisons in this release have been restated. BIO-key will host an investor call Thursday, August 15th at 10:00am ET (details below). Financial Highlights Q2’24 revenues decreased to $1.1M from $1.9M in Q2’23, principally due to a delay in recognition of approximately $450,000 in software license fees generated by the...

Continue reading

FSI ANNOUNCES SECOND QUARTER, 2024 FINANCIAL RESULTS

A CONFERENCE CALL IS SCHEDULED FOR THURSDAY, AUGUST 15, 2024, 11:00AM EASTERN TIME SEE DIAL IN NUMBER BELOW VICTORIA, BRITISH COLUMBIA, Aug. 14, 2024 (GLOBE NEWSWIRE) — FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. Today the Company announces financial results for second quarter ended June 30, 2024. Mr. Daniel B. O’Brien, CEO, states, “The second quarter results are a solid improvement over the year earlier period. We will try to build on these results over the remainder of the year.” Mr. O’Brien continues, “We also hope that the hard...

Continue reading

POET Technologies Reports Second Quarter 2024 Financial Results

Tier One Design Wins and Strong Balance Sheet Support Penetration into AI Networks TORONTO, Aug. 14, 2024 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and artificial intelligence markets, today reported its unaudited condensed consolidated financial results as at and for the three months ended June 30, 2024. The Company’s financial results as well as the Management’s Discussion and Analysis have been filed on SEDAR. All financial figures are in United States dollars (“USD”) unless otherwise indicated. Second Quarter and Recent Business Highlights: The Company announced a major design win with Foxconn Interconnect...

Continue reading

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced that following the release of its second quarter financial results, the Company intends to host a conference call and live webcast on Thursday, August 15, at 8:00 AM ET to provide a corporate update. Conference Call and Webcast InformationDate: Thursday, August 15, 2024Time: 8:00 AM ETWebcast Link: Traws Pharma Corporate Update Call Dial-in Numbers: (877) 407-0789 (United States), (201) 689-8562 (International)Conference ID: 13748066 The press release with the financial results will be accessible prior to the conference call through “Press Releases” in the Investors & Media section of the company’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.